For the study, researchers analyzed 349 antibodies extracted from the blood of one survivor of the West African Ebola outbreak. The team identified two naturally occurring antibodies that offered protection against three of the five species of Ebola virus in the laboratory setting. In animal models, both antibodies each protected mice from two Ebola species.
“Since it’s impossible to predict which of these agents [Ebola species] will cause the next epidemic, it would be ideal to develop a single therapy that could treat or prevent infection caused by any known ebolavirus,” said Zachary Bornholdt, PhD, one of the study’s authors and the director of antibody discovery at Mapp Biopharmaceutical.
More articles on infection control:
NYC police officer contracts Legionnaires’
Kidney disease affects 1 in 7 Americans, says CDC
C. diff infections more common in acute than long-term care settings; antibiotic use to blame
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.